Giant cell arteritis: Diagnosis, management, and cardiovascular implications

Cardiology in Review

Volumn 15, Issue 2, 2007, Pages 55-61

  Eberhardt, Robert T ^a,b   Dhadly, Mandeep ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Giant cell arteritis; Polymyalgia rheumatica; Review; Treatment

Indexed keywords

AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; VASCULOTROPIN; VITAMIN D;

BLINDNESS; BLOOD VESSEL BIOPSY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; INFECTION; LABORATORY TEST; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PATHOPHYSIOLOGY; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; TEMPORAL ARTERY; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION;

ADRENAL CORTEX HORMONES; ADULT; AGE DISTRIBUTION; AGED; DIAGNOSIS, DIFFERENTIAL; EUROPE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; SEX DISTRIBUTION; TAKAYASU'S ARTERITIS; TEMPORAL ARTERIES; TEMPORAL ARTERITIS;

EID: 33847059091     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000218853.05856.b6     Document Type: Review

References (56)

1. Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol. 2004;16:25-30.
2. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006;18:10-17.
3. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
4. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum. 1983;26:1214-1219.
5. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation, 1982-1985. Arthritis Rheum. 1987;30:294-299.
6. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:S9-S11.
7. Ostberg G. Temporal arteritis in a large necropsy series. Ann Rheum Dis. 1971;30:224-235.
8. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-1128.
9. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis. 2001;60:367-371.
10. Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51:264-268.
11. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am. 1995;21:883-909.
12. Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum. 1994;37:514-520.
13. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1999;42:844-853.
14. Weyand CG. Pathogenic principles in giant cell arteritis. Int J Cardiol. 2000;75:S9-15.
15. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497-1504.
16. Liozon E, Herrman F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.
17. Salvaroni C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5 year epidemiologic and clinical study in Reggio Emilio, Italy. Clin Exp Rheumatol. 1987;5:205-215.
18. Klein RG, Hunder GG, Stanson AW, et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. 1975;83:806-812.
19. Pego-Reigosa R, Garcia-Porrua C, Pineiro A, et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol. 2004;22:S13-S17.
20. Pfadenhauer K, Esser M, Berger K. Vertebrobasilar ischemia and structural abnormalities of the vertebral arteries in active temporal arteritis and polymyalgia rheumatica: an ultrasonographic case-control study. J Rheumatol. 2005;32:2356-2360.
21. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83:342-347.
22. Amor-Dorado JC, Liorca J, Garcia-Parrua C, et al. Audiovestibular manifestations in giant cell arteritis: a prospective study. Medicine (Baltimore). 2003;82:13-26.
23. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med. 1995;122:502-507.
24. Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335-341.
25. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532-3537.
26. Evan JM, Bowles CA, Bjornsson, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis: a descriptive study of 41 cases. Arthritis Rheum. 1994;37:422-431.
27. Berry MF, Woo YJ. Repair of acute type A aortic dissection associated with temporal arteritis. Ann Thorac Surg. 2003;76:1717-1718.
28. Le Page L, Duhaut P, Seydoux D, et al. [Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG) {in French}.] Rev Med Interne. 2005 [Epub ahead of print].
29. Freddo T, Price M, Kase C, et al. Myocardial infarction and coronary artery involvement in giant cell arteritis. Optom Vis Sci. 1999;76:14-18.
30. Kumar P, Velissaris T, Sheppard MN, et al. Giant cell arteritis confined to intramural coronary arteries: unforeseen hazards myocardial protection. J Cardiovasc Surg. 2002;43:647-649.
31. Pfizenmaier DH, Al Atawi FO, Castillo Y, et al. Predictors of left ventricular dysfunction in patients with Takayasu's or giant cell aortitis. Clin Exp Rheumatol. 2004;22:S41-S45.
32. Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis. 1989;48:667-671.
33. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2001;45:140-145.
34. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041-1048.
35. Salvarani C, Macchioni P, Boiardi L, et al. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis: clinical and laboratory correlations. J Rheumatol. 1992;19:1100-1106.
36. Poller DN, van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol. 2000;53:137-139.
37. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249-256.
38. Lie JB, Carter ET. Spectrum of aging changes in temporal arteries. Its significance, in interpretation of biopsy of temporal artery. Arch Pathol Lab Med. 1970;90:278-285.
39. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120:987-992.
40. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129:345-352.
41. Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336-1342.
42. Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med. 2002;137:232-238.
43. Pfadenhauer K, Weber H. Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. J Rheumatol. 2003;30:2177-2181.
44. Narvaez J, Narvaez JA, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). 2005;44:479-483.
45. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. 2005;17:9-15.
46. Myles AB, Perera TE, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol. 1992;31:103-105.
47. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098-1103.
48. Nesher G, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol. 1997;15:303-306.
49. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47:733-739.
50. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatic and temporal arteritis. J Rheumatol. 1990;17:1340-1345.
51. Hayreh SS. Steroid therapy for visual loss in patients with giant-cell arteritis. Lancet. 2000;355:1572-1573.
52. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82:613-618.
53. Gabriel SE, Sunku J, Savarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-1878.
54. Jover JA, Hernandez-Garcia C, Morado I, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-114.
55. Hoffman G, Cid M, Hellmann D, et al. A multicenter, randomized, double-blind, placebo-controlled study of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-1318.
56. Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol. 2006;25:109-110.